BROMAZEPAM 1.5 MG
BROMAZEPAM : 1.5 MG · DIN 02171856 · APOTEX INC
Health Canada status: APPROVED
What is BROMAZEPAM?
BROMAZEPAM 1.5 MG contains BROMAZEPAM : 1.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02171856, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 19-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BROMAZEPAM used for?
Short-term, symptomatic relief of manifestations of excessive anxiety in patients with anxiety neurosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02171856 |
|---|---|
| Brand name | BROMAZEPAM |
| Generic / active ingredient | BROMAZEPAM : 1.5 MG |
| Manufacturer | APOTEX INC |
| Strength | 1.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05BA08 BROMAZEPAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 19-Jul-2021 |
How is it administered?
Individualized dosage; usual adult dose 6-18 mg daily in divided doses (up to 30 mg). Start with lowest effective dose for shortest duration. Taper gradually to discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section header exists but content is missing from snippet).
How is it supplied?
Not explicitly detailed in provided text (mentions initial supply should not exceed one week).
Contraindications
Hypersensitivity to benzodiazepines, myasthenia gravis, severe hepatic impairment, severe respiratory insufficiency, sleep apnea syndrome, and narrow angle glaucoma.
Warnings and precautions
Risk of addiction, abuse, misuse, and life-threatening withdrawal. Concomitant use with opioids may result in death. May cause sedation, amnesia, and impaired driving ability.
What can be used instead?
Other Canadian products sharing ATC code N05BA08 BROMAZEPAM. 4 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BROMAZEPAM | 3 MG | TABLET | APOTEX INC | MARKETED | DIN 02177161 |
| APO-BROMAZEPAM | 6 MG | TABLET | APOTEX INC | MARKETED | DIN 02177188 |
| TEVA-BROMAZEPAM | 3 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02230584 |
| TEVA-BROMAZEPAM | 6 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02230585 |
| ALTI-BROMAZEPAM 1.5MG TABLETS | 1.5 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02167808 |
| ALTI-BROMAZEPAM 3MG TABLETS | 3 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02167816 |
| ALTI-BROMAZEPAM 6MG TABLETS | 6 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02167824 |
| APO-BROMAZEPAM | 1.5 MG | TABLET | APOTEX INC | DORMANT | DIN 02177153 |
| BROMAZEPAM | 3 MG | TABLET | APOTEX INC | APPROVED | DIN 02171864 |
| BROMAZEPAM | 6 MG | TABLET | APOTEX INC | APPROVED | DIN 02171872 |
Who else supplies BROMAZEPAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BROMAZEPAM appears in 73 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.